Investor Relations

News Releases

 
News Releases
  Date Title View
Feb 21, 2018
MONOVISC Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017;Total Revenue Increased 10% for Full Year of 2017 BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company spe...
Feb 7, 2018
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:0...
Feb 1, 2018
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced an agreement with the Institute of Integrative Biology at the Uni...
Jan 24, 2018
BEDFORD, Mass.--(BUSINESS WIRE)-- A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company speci...
Dec 27, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its HA-based bone void filler received 510(k) clearance from the U.S. ...
Oct 25, 2017
Completed Enrollment in CINGAL Phase III Clinical Trial;Advancement of Regenerative Medicine Pipeline;MONOVISC Revenue Increased 50% Year-over-Year BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic med...
Oct 25, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the completion of enrollment in its second pivotal Phase III trial evaluat...
Oct 23, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Thomas M. Finnerty as its Chief Human Resources Officer...
Oct 16, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®...
Oct 11, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017, at 9:00 a...
1
... NextLast

= add release to Briefcase